• Conference Proceeding

Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-To-Severe Rheumatoid Arthritis

Citation

Hicks, K. A., Earnshaw, S. R., Shaw, J. W., & Cifaldi, M. (2012). Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-To-Severe Rheumatoid Arthritis. In [15], pp. A439–A440. .

Abstract